combination therapies outperforming semaglutide A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the The evolving landscape of obesity

Push the plunger or press the pen button at a steady, moderate speed rather than forcing the medication in quickly

Manufactured to the highest industry standards, each batch undergoes rigorous testing to ensure unmatched purity, potency, and consistencymaking it ideal for comprehensive scientific research and reliable outcomes

Seek medical help if constipation lasts more than a few days or is accompanied by pain, vomiting, or bleeding, as these can indicate more serious digestive complications

Because semaglutide-induced thyroid C-cell tumors have been reported in rodent studies, semaglutide should not be used in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2